肾移植病史心房颤动患者导管消融的安全性及有效性分析

doi:10.3969/j.issn.1006-7795.2020.03.020

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (3): 433-438.doi: 10.3969/j.issn.1006-7795.2020.03.020

肾移植病史心房颤动患者导管消融的安全性及有效性分析

喻荣辉¹, 汤日波¹, 吴嘉慧¹, 闻松男¹, 林晖²

1. 首都医科大学附属北京安贞医院心脏内科中心, 北京 100029;
2. 北京大学首钢医院心血管内科, 北京 100144

收稿日期:2019-07-17 出版日期:2020-06-21 发布日期:2020-06-17
通讯作者: 林晖 E-mail:cardiologylh@163.com
基金资助:
国家自然科学基金（81770322），北京市科技计划（Z181100001718174）。

Safety and efficacy of catheter ablation for atrial fibrillation patients with history of renal transplantation

Yu Ronghui¹, Tang Ribo¹, Wu Jiahui¹, Wen Songnan¹, Lin Hui²

1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;
2. Department of Cardiovascular, Beijing University Shougang Hospital, Beijing 100144, China

Received:2019-07-17 Online:2020-06-21 Published:2020-06-17
Supported by:
This study was supported by National Natural Science Foundation of China (81770322), Beijing Municipal Science and Technology Project (Z181100001718174).

摘要/Abstract

摘要： 目的本研究讨论有肾移植病史的心房颤动（以下简称房颤）患者行导管消融的安全性及有效性。方法以7例因抗心律失常药物治疗效果不佳而进行射频消融的有肾移植病史的房颤患者为病例组，按照1：6配对原则（年龄、性别和房颤类型）选择对照42例。对比分析复发率、围术期合并症和造影剂肾病发生率。结果两组患者中均无围术期合并症和造影剂肾病的发生。在随访12个月时，有肾移植病史的房颤患者复发率更高（时序检验，P=0.027）。结论有肾移植病史的房颤患者可以安全地施行射频消融术，但这类患者进行消融术后更容易复发。

关键词: 心房颤动, 肾移植, 估测的肾小球滤过率, 导管消融

Abstract: Objective To study the prognosis of catheter ablation in atrial fibrillation (AF) patients with history of renal transplantation. Methods Seven AF patients with renal transplantation history who had received radiofrequency ablation due to the poor effect of antiarrhythmic drugs were selected as the case group, and 42 controls were selected according to the 1:6 matching principle (age, gender and type of atrial fibrillation). The recurrence rate, perioperative complications and the incidence of contrast nephropathy were compared and analyzed. Results No periprocedural complications and contrast nephropathy were observed in either group. During a follow-up period of 12 months, the ATa recurrent rate was higher in AF patients with renal transplantation history (Log rank test, P=0.027). Conclusion Catheter ablation for AF can be safely performed in patients with history of renal transplantation. AF patients with renal transplantation history tend to have higher ATa recurrence after the catheter ablation.

Key words: atrial fibrillation, renal transplantation, estimated glomerular filtration rate, catheter ablation

中图分类号:

喻荣辉, 汤日波, 吴嘉慧, 闻松男, 林晖. 肾移植病史心房颤动患者导管消融的安全性及有效性分析[J]. 首都医科大学学报, 2020, 41(3): 433-438.

Yu Ronghui, Tang Ribo, Wu Jiahui, Wen Songnan, Lin Hui. Safety and efficacy of catheter ablation for atrial fibrillation patients with history of renal transplantation[J]. Journal of Capital Medical University, 2020, 41(3): 433-438.

参考文献

[1] Jun M, James M T, Manns B J, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment:population based observational study[J]. BMJ, 2015, 350:h246.
[2] Ng K P, Edwards N C, Lip G Y, et al. Atrial fibrillation in CKD:balancing the risks and benefits of anticoagulation[J]. Am J Kidney Dis, 2013, 62(3):615-632.
[3] Zimmerman D, Sood M M, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis[J]. Nephrol Dial Transplant, 2012, 27(10):3816-3822.
[4] Lentine K L, Schnitzler M A, Abbott K C, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation[J]. Clin J Am Soc Nephrol, 2006, 1(2):288-296.
[5] Schnuelle P, Lorenz D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure:evidence for reduced mortality risk compared with hemodialysis during long-term follow-up[J]. J Am Soc Nephrol, 1998, 9(11):2135-2141.
[6] Port F K, Wolfe R A, Mauger E A, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients[J]. JAMA, 1993, 270(11):1339-1343.
[7] Ojo A O, Port F K, Wolfe R A, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients[J]. Am J Kidney Dis, 1994,24(1):59-64.
[8] Snyder J J, Kasiske B L, Gilbertson D T, et al. A comparison of transplant outcomes in peritoneal and hemodialysis patients[J]. Kidney Int, 2002, 62(4):1423-1430.
[9] Calkins H, Hindricks G, Cappato R,et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. Europace,2018,20(1):e1-e160.
[10] Ma Y C, Zuo L, Chen J H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(10):2937-2944.
[11] Ohno I, Hayashi H, Aonuma K, et al. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012:digest version:JSN, JRS, and JCS Joint Working Group[J]. Clin Exp Nephrol, 2013, 17(4):441-479.
[12] Liu X, Dong J, Mavrakis H E, et al. Achievement of pulmonary vein isolation in patients undergoing circumferential pulmonary vein ablation:a randomized comparison between two different isolation approaches[J]. J Cardiovasc Electrophysiol, 2006, 17(12):1263-1270.
[13] Schweiger M J, Chambers C E, Davidson C J, et al. Prevention of contrast induced nephropathy:recommendations for the high risk patient undergoing cardiovascular procedures[J]. Catheter Cardiovasc Interv, 2007, 69(1):135-140.
[14] Lentine K L, Schnitzler M A, Abbott K C, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation[J]. Clin J Am Soc Nephrol, 2006, 1(2):288-296.
[15] Yamada T, Kay G N. Catheter ablation of atrial fibrillation in the elderly. Pacing Clin Electrophysiol[J]. 2009, 32(8):1085-1091.
[16] Chugh A, Morady F. Atrial fibrillation:catheter ablation[J]. J Interv Card Electrophysiol, 2006, 16(1):15-26.
[17] Cappato R, Calkins H, Chen S A, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2010, 3(1):32-38.
[18] Wright M, Haïssaguerre M, Knecht S, et al. State of the art:catheter ablation of atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2008, 19(6):583-592.
[19] Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation:a mid-term follow-up[J]. Heart Rhythm, 2011, 8(3):335-341.
[20] Abbott K C, Reynolds J C, Taylor A J, et al. Hospitalized atrial fibrillation after renal transplantation in the United States[J]. Am J Transplant, 2003, 3(4):471-476.
[21] Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation:a randomised multicentre study[J]. Lancet, 2002, 359(9308):741-746.
[22] Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation[J]. Eur Heart J, 2007, 28(7):836-841.
[23] Themistoclakis S, Schweikert R A, Saliba W I, et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation[J]. Heart Rhythm, 2008, 5(5):679-685.
[24] Severi S, Pogliani D, Fantini G, et al. Alterations of atrial electrophysiology induced by electrolyte variations:combined computational and P-wave analysis[J]. Europace, 2010, 12(6):842-849.
[25] Rigatto C, Foley R N, Kent G M, et al. Long-term changes in left ventricular hypertrophy after renal transplantation[J]. Transplantation, 2000, 70(4):570-575.
[26] Chao T F, Lin Y J, Chang S L, et al. Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation[J]. Circ J, 2011, 75(10):2326-2332.
[27] Tanaka K, Zlochiver S, Vikstrom K L, et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure[J]. Circ Res, 2007, 101(8):839-847.

肾移植病史心房颤动患者导管消融的安全性及有效性分析

Safety and efficacy of catheter ablation for atrial fibrillation patients with history of renal transplantation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贾朝旭, 马长生. 改善心血管疾病防治现状,一直在路上——马长生教授[J]. 首都医科大学学报, 2020, 41(5): 834-838.
[2]	善辉, 张鑫, 谷丽, 唐子人, 张小东. 肾移植供体来源性感染的调查及干预[J]. 首都医科大学学报, 2019, 40(5): 764-768.
[3]	张杨, 马展鸿, 蒋涛. 心房颤动患者左房耳形态与血栓及短暂性脑缺血发作关系的研究[J]. 首都医科大学学报, 2019, 40(5): 776-780.
[4]	林涛, 魏欣, 徐晓薇, 马岩, 王蕊, 田俊萍, 郭晓彬, 陈步星. 可调弯鞘在心房颤动环肺静脉隔离术中的应用经验[J]. 首都医科大学学报, 2016, 37(1): 54-57.
[5]	张振华, 张海波, 韩建成, 孟旭, 韩杰, 李岩, 王刚. 外科微创手术治疗心房颤动对左心房功能的影响[J]. 首都医科大学学报, 2015, 36(3): 371-375.
[6]	杨晓勇, 任亮, 王玮, 刘航, 胡小鹏, 张小东. 肾移植受者BK病毒感染的单中心回顾性研究[J]. 首都医科大学学报, 2015, 36(3): 459-464.
[7]	赵秀玲, 王淑珍, 张震宇, 崔秀平, 刘英俏. 生育年龄肾功能不全女性患者月经异常的相关因素分析[J]. 首都医科大学学报, 2013, 34(3): 432-436.
[8]	贾保祥;马威然;田野. 亲属肾移植患者术后肾功能与HLA配型和PRA相关性研究[J]. 首都医科大学学报, 2011, 32(6): 838-842.
[9]	丁毅;张镭;钱晓军;翟仁友;王玮. 肾移植术后肺部特异性感染的CT表现[J]. 首都医科大学学报, 2009, 30(5): 703-709.
[10]	李晓北;石田英树;古泽美由纪;土埼大介;饭田洋一;山口裕;田边一成. 活体肾移植体液性排斥反应与抗HLA抗体的研究[J]. 首都医科大学学报, 2008, 29(2): 237-241.
[11]	穆利英;杜凤和;徐秀英. 非瓣膜性心房颤动患者脑卒中危险因素的临床分析[J]. 首都医科大学学报, 2006, 27(3): 375-378.
[12]	李梅;华琦;刘荣坤;杨铮. 高血压合并心房颤动对内皮细胞功能的影响[J]. 首都医科大学学报, 2005, 26(3): 312-315.
[13]	王长华;胡大一;汤楚中;吴明营;梅运清. 慢性心房颤动患者右心耳IL-1β、IL-6和肿瘤坏死因子-α基因表达的研究[J]. 首都医科大学学报, 2005, 26(2): 111-115.
[14]	刘庆军;徐秀红;张玉海. 前列腺素E₁应用于肾移植受者的实验及临床观察[J]. 首都医科大学学报, 2003, 24(3): 310-313.
[15]	刘静;管德林;高居忠;韩志友;韩修武;张愚;李晓北;田溪泉. CAVH用于肾移植后体内水钠潴留的疗效观察[J]. 首都医科大学学报, 2003, 24(2): 165-168.